Leerink downgraded Opthea (OPT) to Market Perform from Outperform with a price target of $1, down from $12. The firm cites the company ...

Leerink analyst Marc Goodman downgraded Opthea (OPT) to Market Perform from Outperform.Light Up your Portfolio with Spark:Easily identify ...

Fintel reports that on March 24, 2025, Leerink Partners initiated coverage of Medpace Holdings (NasdaqGS:MEDP) with a Market ...

Leerink Partners initiated coverage on shares of Medpace (NASDAQ:MEDP – Free Report) in a research note released on Monday morning, Marketbeat.com reports. The brokerage issued a market perform rating ...

Fintel reports that on March 21, 2025, Leerink Partners downgraded their outlook for Elevation Oncology (NasdaqGS:ELEV) from ...

Research analysts at Leerink Partnrs lifted their Q1 2025 earnings estimates for shares of Beam Therapeutics in a research ...

Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced that the ...

Great. So, good morning everybody. Thank you for joining us for our next session here at the Leerink Global Healthcare Conference. It's very much my pleasure to welcome Roland Chen who is Head of ...

today announced its participation in a fireside chat at the Leerink Healthcare Conference on Wednesday, March 12, 2025 at 10:00 a.m. ET. A live webcast will be available on the Investors & Media ...

On Tuesday, 11 March 2025, MacroGenics (NASDAQ: MGNX) presented at Leerink’s Global Healthcare Conference 2025. The company showcased its robust pipeline of cancer therapeutics and strategic ...